HTTP/1.0 200 OK Content-Type: text/html
Pubdate: Thu, 05 Nov 2020 Source: Wall Street Journal (US) Copyright: 2020 Dow Jones & Company, Inc. Contact: http://www.wsj.com/ Details: http://www.mapinc.org/media/487 Author: Donald Morrison OREGON VOTES TO DECRIMINALIZE ALL DRUGS, ALLOW PSILOCYBIN FOR MENTAL HEALTH TREATMENT Oregon became the first state in the nation to decriminalize the possession of all illegal drugs and also legalize the use of psilocybin-the active ingredient in hallucinogenic mushrooms-for mental health treatment, after voters passed a pair of ballot measures this week. Both are the first of their kind in any U.S. state and represent the next frontier in the relaxation of drug laws beyond marijuana. With results from 76% of precincts reporting early Wednesday morning, 59% of Oregonians approved Measure 110, the drug decriminalization referendum, and 56% voted for Measure 109 on psilocybin therapy, according to the Associated Press. "There are a lot of parallels between what Oregon is trying to do now and what states were doing with marijuana 40 years ago," said Robert Mikos, a law professor at Vanderbilt University who has written about marijuana legalization. "As long as the sky doesn't fall in Oregon, some other states might follow suit." Also Tuesday, voters in the District of Columbia approved a measure decriminalizing psilocybin. With 61% of precincts there reporting, support was at 76%, according to the AP. Several cities previously passed similar measures, including Oakland and Santa Cruz in California, as well as Denver. Measures legalizing possession of marijuana for recreational or medical reasons passed in Arizona, Montana, New Jersey and South Dakota according to the AP. Oregon's Measure 110 makes possession of any controlled substance, including heroin, cocaine or methamphetamines, a violation punishable by a maximum fine of $100 or a completed health assessment. It also establishes a new statewide drug treatment system funded in part by tax revenue from marijuana sales and state prison savings. The campaign in favor of Measure 110 raised $4.5 million and the one for Measure 109 raised $5.7 million, while opposing campaigns raised virtually nothing, according to campaign finance reports. Proponents of Measure 110, including the Democratic Party of Oregon and the American Civil Liberties Union of Oregon, said people suffering with addiction should have greater access to rehabilitation and not face criminal punishment. "We don't have enough tools in our toolbox, there's just no question about that," said Democratic State Sen. Elizabeth Steiner Hayward, from Portland. Oregon was the first state to decriminalize the possession of cannabis, for similar reasons, in 1973. Many of the state's district attorneys and Republican politicians said the new measure was counterproductive because the threat of criminal penalties helped to push some addicts to accept treatment. Measure 109, meanwhile, gives the state public health department two years to develop regulations and create a program responsible for manufacturing and dispensing psilocybin to adults aged 21 or older seeking therapy with a trained facilitator for everything from post-traumatic stress disorder to nicotine dependence. "We're going to take our time and do it right," said Tom Eckert, a psychotherapist who was a chief sponsor of the bill along with his psychotherapist wife Sheri. "We're in a mental health crisis and we need new treatment options." Like cannabis, the Drug Enforcement Administration classifies psilocybin as a Schedule 1 drug, meaning it isn't approved for medical use and there's a high potential for abuse and addiction. Psilocybin is a naturally occurring chemical in more than 200 species of fungi that can cause visual and auditory hallucinations and an inability to discern fantasy from reality. Research has shown that it can reduce anxiety and stress among cancer patients and people diagnosed with PTSD. Some supporters of its medical use also say it can be helpful for anyone looking for help with a persistent mental health issue. But the Oregon Psychiatric Physicians Association and the American Psychiatric Association opposed the measure, arguing that there isn't enough evidence to support psilocybin's use in mental health treatment. "Psilocybin research trials are in the early stages," said OPPA President Nicole Cirino. "We need to know what type of mental illness it actually treats and what safety precautions, doses, follow up measures we need in place to use it safely and effectively. - --- MAP posted-by: Matt